Tilray Brands (NASDAQ:TLRY) Price Target Cut to $9.00 by Analysts at ATB Cormark Capital Markets

Tilray Brands (NASDAQ:TLRY) had its price objective reduced by ATB Cormark Capital Markets from $9.50 to $9.00 in a research report sent to investors on Thursday,BayStreet.CA reports. ATB Cormark Capital Markets currently has a sector perform rating on the stock.

TLRY has been the subject of a number of other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tilray Brands in a research report on Wednesday, January 21st. Wall Street Zen upgraded shares of Tilray Brands from a “sell” rating to a “hold” rating in a research note on Saturday, March 21st. Zacks Research upgraded Tilray Brands from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 11th. TD Cowen lowered their target price on Tilray Brands from $10.00 to $7.00 and set a “buy” rating on the stock in a research report on Monday. Finally, Canaccord Genuity Group started coverage on Tilray Brands in a report on Tuesday, January 27th. They set a “hold” rating on the stock. Three investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Tilray Brands presently has a consensus rating of “Hold” and a consensus price target of $11.20.

Tilray Brands Trading Up 6.7%

NASDAQ:TLRY opened at $6.55 on Thursday. The company has a market cap of $763.14 million, a P/E ratio of -0.48 and a beta of 2.00. Tilray Brands has a twelve month low of $3.51 and a twelve month high of $23.20. The business has a 50 day moving average price of $7.32 and a two-hundred day moving average price of $10.23. The company has a quick ratio of 1.72, a current ratio of 2.81 and a debt-to-equity ratio of 0.19.

Tilray Brands (NASDAQ:TLRY) last posted its quarterly earnings data on Wednesday, April 1st. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.10). The business had revenue of $206.73 million during the quarter, compared to analyst estimates of $201.35 million. Tilray Brands had a negative net margin of 156.51% and a negative return on equity of 3.31%. During the same quarter last year, the business earned ($0.87) earnings per share. As a group, analysts expect that Tilray Brands will post -0.2 EPS for the current fiscal year.

Institutional Trading of Tilray Brands

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Hilton Head Capital Partners LLC bought a new position in shares of Tilray Brands in the 4th quarter valued at about $38,000. Schonfeld Strategic Advisors LLC raised its holdings in shares of Tilray Brands by 4.5% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 144,358 shares of the company’s stock valued at $1,304,000 after purchasing an additional 6,182 shares during the period. IFP Advisors Inc lifted its stake in Tilray Brands by 14.3% in the 4th quarter. IFP Advisors Inc now owns 60,318 shares of the company’s stock valued at $545,000 after purchasing an additional 7,541 shares during the last quarter. Integrated Wealth Concepts LLC lifted its stake in Tilray Brands by 33.8% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 36,977 shares of the company’s stock valued at $64,000 after purchasing an additional 9,341 shares during the last quarter. Finally, CreativeOne Wealth LLC grew its holdings in Tilray Brands by 12.2% during the third quarter. CreativeOne Wealth LLC now owns 87,134 shares of the company’s stock worth $151,000 after purchasing an additional 9,452 shares during the period. 9.35% of the stock is owned by institutional investors.

Tilray Brands News Summary

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: Roth upgraded Tilray to Buy after Q3 results, citing the company’s improving outlook and execution—this upgrade helped lift sentiment. Tilray rebounds as Roth Capital upgrades to Buy after Q3 results
• Positive Sentiment: Jefferies reiterated a Buy and kept a high $24 price target, highlighting strong cannabis sales and increased visibility into medium‑term results—this signals confidence from a major broker. Tilray Brands’ strong cannabis sales and upbeat outlook keeps Jefferies analysts bullish
• Positive Sentiment: Tilray reported record Q3 revenue (~$207M), 11% organic growth, gross profit expansion (~$55M) and a 73% jump in international cannabis revenue—management reaffirmed FY26 guidance, which supports the constructive narrative. Tilray Brands Delivers Record Q3 Fiscal 2026 Results
• Positive Sentiment: Sector tailwind: the FDA signaled it won’t enforce some CBD rules, which lifted cannabis/CBD names broadly and supports Tilray’s consumer-facing opportunity. Why Tilray and Other Cannabis Stocks Just Had Their Best Week of 2026
• Neutral Sentiment: Zacks and other analysts describe Q3 as mixed—revenue and narrowing losses are positives, but beverage weakness and margin pressure temper the bullish case. Should Tilray Brands Be in Your Portfolio Post Q3 Earnings?
• Neutral Sentiment: Analysis pieces note improving fundamentals but flag negative cash flow and execution/M&A risk—supportive for medium-term upside but caution on near-term volatility. Tilray Brands Is Looking Better
• Negative Sentiment: Tilray missed EPS expectations (loss of $0.24 vs. est. -$0.14), and investors have been wary of margin compression and beverage-segment softness—these factors triggered earlier intraday selling. Earnings and conference call details
• Negative Sentiment: Some analysts trimmed targets/ratings after the print: ATB Cormark cut its target to $9.00 (sector perform) and TD Cowen lowered expectations—mixed analyst action adds selling pressure at current levels. Analyst rating changes TD Cowen lowers expectations

Tilray Brands Company Profile

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.